Cyclic ureas as inhibitors of rock

A compound according to Formula (IIa):

• or an enantiomer, a diastereomer, a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof, wherein
• is an optional bond;
• Ring A is independently selected from
• R1 is independently selected from H, F, Cl, Br, CN, NRaRa, and C1-4alkyl substituted with 0-4 Re;
• R2 is independently selected from H, F, Cl, Br, OH, CN, NRaRa, and C1-4alkyl substituted with 0-4 Re;
• R3 is independently selected from H, F, Cl, Br, CN, C1-4 alkyl substituted with 0-3 Re, —(CH2)rORb, and —C3-6 cycloalkyl;
• R4 is independently selected from H, F, Cl, Br, OH, CN, OC1-4 alkyl substituted with 0-3 Re, and C1-4 alkyl substituted with 0-3 Re;
• R5, R10, and R11 are independently selected from H, ═O, and C1-4alkyl substituted with 0-4 Re;
• provided R5, R10, and R11 are not all H;
• R6 and R7 are independently selected from H, C1-4alkyl substituted with 0-4 Re, —(CH2)rORb, —(CH2)rC(═O)Rb, —(CH2)rNRaRa, —(CH2)rC(═O)NRaRa, —(CH2)rNRaC(═O)Rb, —(CH2)rC(═O)ORb, (CH2)r—C3-6 carbocyclyl substituted with 0-3 Re, and —(CH2)r-heterocyclyl substituted with 0-3 Re;
• R9 is independently selected from F, Cl, Br, C1-4 alkyl, nitro, —(CH2)rS(O)pRc, —(CH2)rS(O)pNRaRa, —(CH2)rNRaS(O)pRb, —(CH2)rORb, —(CH2)rCN, —(CH2)rNRaRa, —(CH2)rNRaC(═O)Rb, —(CH2)rNRaC(═O)NRaRa, —(CH2)rC(═O)ORb, —(CH2)rC(═O)Rb, —(CH2)rOC(═O)Rb, —(CH2)r-cycloalkyl, —(CH2)r-heterocyclyl, —(CH2)r-aryl, and —(CH2)r-heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is substituted with 0-4 Re;
• Ra, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, —(CH2)r—C3-10cycloalkyl substituted with 0-5 Re, —(CH2)r-aryl substituted with 0-5 Re, and —(CH2)r-heterocyclyl substituted with 0-5 Re;
• or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;
• Rb, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, —(CH2)r—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)r-heterocyclyl substituted with 0-5 Re;
• Rc, at each occurrence, is independently selected from C1-6 alkyl substituted with 0-5 Re, C2-6alkenyl substituted with 0-5 Re, C2-6alkynyl substituted with 0-5 Re, C3-6carbocyclyl, and heterocyclyl;
• Re, at each occurrence, is independently selected from C1-6 alkyl substituted with 0-5 Rf, C2-6 alkenyl, C2-6 alkynyl, —(CH2)r—C3-6 cycloalkyl, —(CH2)r—C4-6 heterocyclyl, F, Cl, Br, CN, NO2, ═O, CO2H, —(CH2)rORf, S(O)pRf, S(O)pNRfRf, and —(CH2)rNRfRf;
• Rf, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C1-5 alkyl, C3-6 cycloalkyl, and phenyl, or Rf and Rf together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with C1-4alkyl;
• n is independently selected from 1, 2, and 3;
• p, at each occurrence, is independently selected from zero, 1, and 2;
• and
• r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4;
• and
• provided
• (1) R9 is not a substituted piperazine;
• (2) when n is 3, R8 is not
• and
• (3) when A is
• R2 is not —C(═O)NRaRa, —NRaC(═O)Rb, and —NRaC(═O)NRaRa.

A compound according to Formula (XIII):

• or an enantiomer, a diastereomer, a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof, wherein
• Ring A is independently selected from
• J1, J2, J3, and J4 are independently selected from N and CR3;
• K is independently selected from N and CR1;
• R1 is independently selected from H, F, Cl, Br, OH, CN, NRaRa, —OC1-4 alkyl substituted with 0-3 Re, and C1-4 alkyl substituted with 0-3 Re;
• R2 is independently selected from H, —(CH2)rORb, (CH2)rS(O)pRc, —(CH2)rC(═O)Rb, —(CH2)rNRaRa, —(CH2)rCN, —(CH2)rC(═O)NRaRa, —(CH2)rNRaC(═O)Rb, —(CH2)rNRaC(═O)NRaRa, —(CH2)rNRaC(═O)ORb, —(CH2)rOC(═O)NRaRa, —(CH2)rC(═O)ORb, —(CH2)rS(O)pNRaRa, —(CH2)rNRaS(O)pNRaRa, —(CH2)rNRaS(O)pRc, (CH2)r—C3-6 carbocyclyl substituted with 0-3 Re, and —(CH2)r-heterocyclyl substituted with 0-3 Re;
• R3 is independently selected from H, F, Cl, Br, CN, C1-4 alkyl substituted with 0-3 Re, —(CH2)rORb, (CH2)rS(O)pRc, —(CH2)rC(═O)Rb, —(CH2)rNRaRa, —(CH2)rC(═O)NRaRa, —(CH2)rC(═O)(CH2)rNRaRa, —(CH2)rCN, —(CH2)rNRaC(═O)Rb, —(CH2)rNRaC(═O)ORb, —(CH2)rOC(═O)NRaRa, —(CH2)rNRaC(═O)NRaRa, —(CH2)rC(═O)ORb, —(CH2)rS(O)pNRaRa, —(CH2)rNRaS(O)pNRaRa, —(CH2)rNRaS(O)pRc, (CH2)r—C3-6 carbocyclyl substituted with 0-3 Re, and —(CH2)r-heterocyclyl substituted with 0-3 Re;
• R4 is independently selected from H, F, Cl, Br, OH, CN, OC1-4 alkyl substituted with 0-3 Re, NRaRa, and C1-4 alkyl substituted with 0-3 Re;
• R5 is independently selected from H, ═O, C1-4alkyl substituted with 0-4 Re, —(CH2)rORb, (CH2)rS(O)pRc, —(CH2)rC(═O)Rb, —(CH2)rNRaRa, —(CH2)rCN, —(CH2)rC(═O)NRaRa, —(CH2)rNRaC(═O)Rb, —(CH2)rNRaC(═O)NRaRa, —(CH2)rNRaC(═O)ORb, —(CH2)rOC(═O)NRaRa, —(CH2)rC(═O)ORb, —(CH2)rS(O)pNRaRa, —(CH2)rNRaS(O)pNRaRa, —(CH2)rNRaS(O)pRc, (CH2)r—C3-6 carbocyclyl substituted with 0-3 Re, and —(CH2)r-heterocyclyl substituted with 0-3 Re;
• R6 and R7 are independently selected from H, C1-4alkyl substituted with 0-4 Re, —(CH2)rORb, —(CH2)rS(O)pRc, —(CH2)rC(═O)Rb, —(CH2)rNRaRa, —(CH2)rC(═O)NRaRa, —(CH2)rC(═O)(CH2)rNRaRa, —(CH2)rNRaC(═O)Rb, —(CH2)rNRaC(═O)ORb, —(CH2)rOC(═O)NRaRa, —(CH2)rNRaC(═O)NRaRa, —(CH2)rC(═O)ORb, —(CH2)rS(O)pNRaRa, —(CH2)rNRaS(O)pNRaRa, —(CH2)rNRaS(O)pRc, (CH2)r—C3-6 carbocyclyl substituted with 0-3 Re, and —(CH2)r-heterocyclyl substituted with 0-3 Re;
• R8 is independently selected from C3-6 cycloalkyl, heterocyclyl, aryl and heteroaryl, each substituted with 0-5 R9;
• R9 is independently selected from F, Cl, Br, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, nitro, —(CHRd)rS(O)pRc, —(CHRd)rS(O)pNRaRa, —(CHRd)rNRaS(O)pRc, —(CHRd)rORb, —(CHRd)rCN, —(CHRd)rNRaRa, —(CHRd)rNRaC(═O)Rb, —(CHRd)rNRaC(═O)NRaRa, —(CHRd)rC(═O)ORb, —(CHRd)rC(═O)Rb, —(CHRd)rOC(═O)Rb, —(CHRd)r-cycloalkyl, —(CHRd)r-heterocyclyl, —(CHRd)r-aryl, and —(CHRd)r-heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is substituted with 0-4 Re;
• Ra, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, —(CH2)rC3-10carbocyclyl substituted with 0-5 Re, and —(CH2)r-heterocyclyl substituted with 0-5 Re;
• or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;
• Rb, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, —(CH2)r—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)r-heterocyclyl substituted with 0-5 Re;
• Rc, at each occurrence, is independently selected from C1-6 alkyl substituted with 0-5 Re, C2-6alkenyl substituted with 0-5 Re, C2-6alkynyl substituted with 0-5 Re, C3-6carbocyclyl, and heterocyclyl;
• Rd, at each occurrence, is independently selected from H and C1-4alkyl substituted with 0-5 Re;
• Re, at each occurrence, is independently selected from C1-6 alkyl substituted with 0-5 Rf, C2-6 alkenyl, C2-6 alkynyl, —(CH2)r—C3-6 cycloalkyl, —(CH2)r—C4-6 heterocyclyl, —(CH2)r-aryl, —(CH2)r-heteroaryl, F, Cl, Br, CN, NO2, ═O, CO2H, —(CH2)rORf, S(O)pRf, C(═O)NRfRf, NRfC(═O)Rd, S(O)pNRfRf, NRfS(O)pRd, NRfC(═O)ORd, OC(═O)NRfRf and —(CH2)rNRfRf;
• Rf, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C1-5alkyl, C3-6 cycloalkyl, and phenyl, or Rf and Rf together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with C1-4alkyl;
• n is independently selected from 1, 2, and 3;
• p, at each occurrence, is independently selected from zero, 1, and 2;
• and
• r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4;
• and
• provided R9 is not a substituted piperazine.